Cue Biopharma Inc EV/EBITDA
¿Qué es el EV/EBITDA de Cue Biopharma Inc?
El EV/EBITDA de Cue Biopharma Inc es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Cue Biopharma Inc
¿Qué hace Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Empresas con ev/ebitda similar a Cue Biopharma Inc
- Trilogy International Partners tiene EV/EBITDA de N/A
- Worldwide tiene EV/EBITDA de N/A
- Myanmar Investments International tiene EV/EBITDA de N/A
- Oshidori International tiene EV/EBITDA de N/A
- Target Capital tiene EV/EBITDA de N/A
- Gold State Resources tiene EV/EBITDA de N/A
- Cue Biopharma Inc tiene EV/EBITDA de N/A
- Entheon Biomedical tiene EV/EBITDA de N/A
- Vantex Resources Ltd tiene EV/EBITDA de N/A
- Made.Com Plc Ord Gbp0.000 tiene EV/EBITDA de N/A
- Skychain Technologies tiene EV/EBITDA de N/A
- 5paisa Capital tiene EV/EBITDA de N/A
- Catenae Innovation Plc tiene EV/EBITDA de N/A